NGENEBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,985 KRW | -4.32% |
|
-3.28% | -28.33% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 11.02B 8.11M | Sales 2023 | 4.35B 3.2M | Capitalization | 71.66B 52.74M |
|---|---|---|---|---|---|
| Net income 2022 | -9.78B -7.2M | Net income 2023 | -12.77B -9.4M | EV / Sales 2022 | 8.4 x |
| Net cash position 2022 | 23.46B 17.27M | Net cash position 2023 | 10.98B 8.08M | EV / Sales 2023 | 13.9 x |
| P/E ratio 2022 |
-11.8
x | P/E ratio 2023 |
-5.52
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.59% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.08% | ||
| 1 week | +1.09% | ||
| Current month | -1.65% | ||
| 1 month | -37.37% | ||
| 3 months | -7.44% | ||
| 6 months | -22.58% | ||
| Current year | -25.09% |
1 week
4 080.00
4 360.00
1 month
4 080.007 360.00
Current year
3 995.007 360.00
1 year
3 995.009 800.00
3 years
3 995.0027 550.00
5 years
3 995.0040 900.00
10 years
3 995.0040 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dae-Chul Choi
CEO | Chief Executive Officer | 52 | - |
Kwang-Joong Kim
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Se-Hyuk Yoon
PRN | Corporate Officer/Principal | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mahn-Soon Hwang
BRD | Director/Board Member | 54 | - |
Young-Ho Moon
BRD | Director/Board Member | 62 | - |
Dae-Chul Choi
CEO | Chief Executive Officer | 52 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 3,985 | -4.32% | 267 682 |
| 24-05-03 | 4,165 | +2.08% | 124,591 |
| 24-05-02 | 4,080 | -3.66% | 368,340 |
| 24-04-30 | 4,235 | +2.79% | 735,638 |
End-of-day quote Korea S.E., May 02, 2024
More quotes
NGeneBio Co Ltd is a Korea-based company engaged in the manufacture and sale of precision diagnostic products. The Company's main products include BRCAaccuTest products used for hereditary breast and ovarian cancer testing, HEMEaccuTest products that tests the causative genes related to blood cancer such as leukemia, lymphoma, and bone marrow cancer, SOLIDaccuTest products that test the causative genes of solid cancer tissues such as lung cancer, colon cancer and stomach cancer. In addition, the Company manufactures and sells products of HLAaccuTest products that tests tissue-specific antigens used for bone marrow transplantation, ONCOaccuPanel products for precise diagnosis of large-capacity solid cancer, HEREDaccuTest products for precise diagnosis for rare diseases. The Company also provides services such as genetic testing direct to customer(DTC) and personalized healthcare.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -25.09% | 39.56M | |
| -1.19% | 12.65B | |
| -6.06% | 8.01B | |
| -0.28% | 5.35B | |
| +21.79% | 5.23B | |
| +2.05% | 4.69B | |
| -51.30% | 3.26B | |
| +7.80% | 2.64B | |
| -8.63% | 2.23B | |
| -0.96% | 1.94B |
- Stock Market
- Equities
- A354200 Stock